HTRA1

Across TCGA pan-cancer cohorts, HTRA1 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated HTRA1 data layer compared with 27 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher HTRA1 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated HTRA1 expression acts as an unfavorable survival marker, although some lineages such as HNSC show a favorable association.

PDAC, LUAD, and CCRCC are the cancer types where HTRA1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	II,III,IV	0.407	0.624	<.001	74	view →
LUAD	OS	Median	II,III,IV	0.795	1.000	.005	16	view →
CCRCC	DFS	Tertile	All	0.709	1.000	.027	11	view →
LSCC	OS	Tertile	All	0.748	0.915	.017	10	view →
GBM	DFS	Tertile	All	0.261	0.457	.026	3	view →
HNSC	DFS	Quartile	All	1.000	0.916	.038	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

HTRA1–PDAC (OS)

Open the PDAC breakdown →